We are live on ! Find out more
AUGX

Augmedix, Inc. Common Stock

Delisted

AUGX was delisted on the 1st of October, 2024.

84 hedge funds and large institutions have $162M invested in Augmedix, Inc. Common Stock in 2024 Q1 according to their latest regulatory filings, with 19 funds opening new positions, 37 increasing their positions, 18 reducing their positions, and 19 closing their positions.

New
Increased
Maintained
Reduced
Closed

106% more repeat investments, than reductions

Existing positions increased: 37 | Existing positions reduced: 18

7% more call options, than puts

Call options by funds: $2.21M | Put options by funds: $2.07M

0% more first-time investments, than exits

New positions opened: 19 | Existing positions closed: 19

1% less funds holding

Funds holding: 8584 (-1)

23% less capital invested

Capital invested by funds: $209M → $162M (-$47.4M)

33% less funds holding in top 10

Funds holding in top 10: 32 (-1)

Holders
84
Holders Change
-1
Holders Change %
-1.18%
% of All Funds
1.21%
Holding in Top 10
2
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-33.33%
% of All Funds
0.03%
New
19
Increased
37
Reduced
18
Closed
19
Calls
$2.21M
Puts
$2.07M
Net Calls
+$142K
Net Calls Change
-$447K
Name Holding Trade Value Shares
Change
Change in
Stake
Goldman Sachs
26
Goldman Sachs
New York
$845K +$678K +151,478 +274%
William Blair & Company
27
William Blair & Company
Illinois
$808K +$207K +46,265 +31%
RCAP
28
Resolute Capital Asset Partners
Colorado
$693K -$425K -95,000 -36%
Jane Street
29
Jane Street
New York
$659K +$161K +36,087 +29%
LCM
30
Laurion Capital Management
New York
$658K
CM
31
Caption Management
Oklahoma
$642K +$702K +157,000 New
BlackRock
32
BlackRock
New York
$628K -$110K -24,600 -14%
BFM
33
Boothbay Fund Management
New York
$621K +$34.4K +7,696 +5%
Man Group
34
Man Group
United Kingdom
$597K +$285K +63,649 +77%
Boston Partners
35
Boston Partners
Massachusetts
$566K +$243K +54,372 +65%
LM
36
Luminus Management
Texas
$557K +$609K +136,155 New
Two Sigma Investments
37
Two Sigma Investments
New York
$547K -$547K -122,227 -48%
State Street
38
State Street
Massachusetts
$522K -$15.7K -3,500 -3%
Two Sigma Advisers
39
Two Sigma Advisers
New York
$415K -$601K -134,300 -57%
JF
40
Jump Financial
Illinois
$413K +$147K +32,771 +48%
Northern Trust
41
Northern Trust
Illinois
$412K +$72.1K +16,104 +19%
Squarepoint
42
Squarepoint
New York
$405K +$443K +99,124 New
DSCM
43
Divisadero Street Capital Management
Florida
$365K -$7.55M -1,687,217 -95%
XT
44
XTX Topco
Cayman Islands
$352K +$385K +86,030 New
Renaissance Technologies
45
Renaissance Technologies
New York
$328K -$769K -171,900 -68%
CSS
46
Cubist Systematic Strategies
Connecticut
$328K +$96.4K +21,546 +37%
SEI Investments
47
SEI Investments
Pennsylvania
$321K -$3.33K -744 -0.9%
Simplex Trading
48
Simplex Trading
Illinois
$319K +$349K +78,071 New
Walleye Capital
49
Walleye Capital
New York
$256K -$460K -102,887 -62%
EGM
50
Engineers Gate Manager
New York
$245K +$137K +30,700 +105%

AUGX Hedge Fund Activity: Q1 2024 in Review

84 of the 6,942 institutional investors tracked by Wall St. Rank reported a position in Augmedix, Inc. Common Stock (AUGX) for Q1 2024, worth a combined $162M — down 23% from $209M a quarter earlier.

Fund positioning in AUGX was balanced in Q1 2024: 19 funds opened new positions, 19 closed out, 37 added to existing stakes and 18 trimmed.

The largest buyer was Citadel Advisors, adding an estimated $8.13M. The largest seller was Divisadero Street Capital Management, cutting an estimated $7.55M.

  • 84 institutional investors held Augmedix, Inc. Common Stock (AUGX) as of Q1 2024, down from 85 in Q4 2023.
  • Funds reported $162M of Augmedix, Inc. Common Stock stock for Q1 2024, down 23% quarter-over-quarter.
  • 19 funds opened new Augmedix, Inc. Common Stock positions in Q1 2024 and 19 closed out, a net change of 0 holders.
  • The largest Augmedix, Inc. Common Stock buyer in Q1 2024 was Citadel Advisors, an estimated $8.13M added.
  • The largest Augmedix, Inc. Common Stock seller in Q1 2024 was Divisadero Street Capital Management, an estimated $7.55M sold.

Based on aggregated 13F filings for Q1 2024.